

Francesco Panza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5850993/publications.pdf>

Version: 2024-02-01

411
papers

42,721
citations

9756

73
h-index

2736

192
g-index

419
all docs

419
docs citations

419
times ranked

55948
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. <i>GeroScience</i> , 2022, 44, 835-845.	2.1	12
2	Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study. <i>Nutritional Neuroscience</i> , 2022, 25, 1300-1309.	1.5	15
3	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. <i>Age and Ageing</i> , 2022, 51, .	0.7	5
4	The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy. <i>Psychiatry Research</i> , 2022, 308, 114346.	1.7	3
5	Mediterranean Diet and Fatty Liver Risk in a Population of Overweight Older Italians: A Propensity Score-Matched Case-Cohort Study. <i>Nutrients</i> , 2022, 14, 258.	1.7	5
6	Frailty and outcome after traumatic brain injury. <i>Lancet Neurology</i> , The, 2022, 21, 107-108.	4.9	6
7	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210816.	1.1	8
8	Association of Neuroretinal Thinning and Microvascular Changes with Hypertension in an Older Population in Southern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1098.	1.0	6
9	Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 632.	1.4	7
10	Dietary Patterns Associated with Diabetes in an Older Population from Southern Italy Using an Unsupervised Learning Approach. <i>Sensors</i> , 2022, 22, 2193.	2.1	11
11	Dietary Customs and Social Deprivation in an Aging Population From Southern Italy: A Machine Learning Approach. <i>Frontiers in Nutrition</i> , 2022, 9, 811076.	1.6	6
12	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. <i>GeroScience</i> , 2022, 44, 1373-1392.	2.1	36
13	Clinical Indicators of Oral Frailty: A Domain-Specific Frailty Phenotype. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2391-2394.	1.0	4
14	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	1.9	6
15	Motoric Cognitive Risk Syndrome, Subtypes and 8-Year All-Cause Mortality in Aging Phenotypes: The Salus in Apulia Study. <i>Brain Sciences</i> , 2022, 12, 861.	1.1	7
16	Coffee Drinking and Adverse Physical Outcomes in the Aging Adult Population: A Systematic Review. <i>Metabolites</i> , 2022, 12, 654.	1.3	4
17	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2169-2177.	1.7	6
18	Late-life depression and its impact on rehabilitation after traumatic injuries. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2313-2316.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 325-337.	0.9	2
20	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. <i>GeroScience</i> , 2021, 43, 1003-1014.	2.1	6
21	Oral frailty and neurodegeneration in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2021, 16, 2149.	1.6	34
22	Vitamin D in the development and progression of Alzheimer's disease: implications for clinical management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 287-301.	1.4	9
23	Cognitive frailty. , 2021, , 463-476.		2
24	How gait influences frailty models and health-related outcomes in clinical-based and population-based studies: a systematic review. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 274-297.	2.9	52
25	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 598-605.	1.2	53
26	Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1695.	1.0	11
27	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 629017.	1.7	4
28	Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy. <i>European Journal of Neurology</i> , 2021, 28, 2565-2573.	1.7	23
29	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 561.	1.2	31
30	Oral frailty and its determinants in older age: a systematic review. <i>The Lancet Healthy Longevity</i> , 2021, 2, e507-e520.	2.0	89
31	COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1-7.	1.0	11
32	Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 193-211.	2.9	54
33	Cross-sectional and longitudinal associations between adherence to Mediterranean diet with physical performance and cognitive function in older adults: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 70, 101395.	5.0	95
34	Associations between nutritional frailty and 8-year all-cause mortality in older adults: The Salus in Apulia Study. <i>Journal of Internal Medicine</i> , 2021, 290, 1071-1082.	2.7	31
35	How many frailties exist? " Authors' reply. <i>The Lancet Healthy Longevity</i> , 2021, 2, e616.	2.0	1
36	More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy. <i>Respiratory Research</i> , 2021, 22, 16.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 853-857.	1.0	14
38	Beverages Consumption and Oral Health in the Aging Population: A Systematic Review. <i>Frontiers in Nutrition</i> , 2021, 8, 762383.	1.6	21
39	Consumption of processed meat may increase the risk of incident late-onset depression. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119225.	0.3	0
40	Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. <i>Biomedicines</i> , 2021, 9, 1617.	1.4	2
41	Could epigenetics play a role in suicidal behavior in older age?. <i>Epigenomics</i> , 2021, , .	1.0	1
42	Retinal Vascular Density on OCT-A and Age-Related Central and Peripheral Hearing Loss in an Italian Older Population. <i>Innovation in Aging</i> , 2021, 5, 155-155.	0.0	0
43	Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12979.	1.2	6
44	Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748888.	1.7	12
45	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. <i>Scientific Reports</i> , 2021, 11, 24084.	1.6	9
46	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. <i>International Journal of Epidemiology</i> , 2020, 49, 173-192.	0.9	44
47	Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 919-933.	1.9	22
48	Frontal lobe syndrome and dementias. , 2020, , 617-632.		1
49	Age-related hearing loss and neuropathologic burden. <i>Neurology</i> , 2020, 95, 511-512.	1.5	8
50	Anti-amyloid- β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	1.0	57
51	Adherence to a Mediterranean Diet and Thyroid Function in Obesity: A Cross-Sectional Apulian Survey. <i>Nutrients</i> , 2020, 12, 3173.	1.7	18
52	Activity Energy Expenditure Predicts Clinical Average Levels of Physical Activity in Older Population: Results from Salus in Apulia Study. <i>Sensors</i> , 2020, 20, 4585.	2.1	11
53	Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12065.	1.8	21
54	Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty. <i>Ageing Research Reviews</i> , 2020, 64, 101148.	5.0	43

#	ARTICLE	IF	CITATIONS
55	Age-related hearing loss and speech perception disorder: the broken interface between healthcare professionals and older adults. <i>European Geriatric Medicine</i> , 2020, 11, 893-895.	1.2	4
56	The relationship between epigenetics and microbiota in neuropsychiatric diseases. <i>Epigenomics</i> , 2020, 12, 1559-1568.	1.0	11
57	A multidimensional frailty approach in predicting and preventing dementia. <i>The Lancet Healthy Longevity</i> , 2020, 1, e49-e50.	2.0	3
58	Social Frailty in the COVID-19 Pandemic Era. <i>Frontiers in Psychiatry</i> , 2020, 11, 577113.	1.3	20
59	Can pharmacotherapy effectively reduce Alzheimer's related agitation?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1517-1522.	0.9	4
60	Social determinants of late-life depression epigenetics. <i>Epigenomics</i> , 2020, 12, 559-562.	1.0	10
61	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 213-228.	4.9	73
62	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 426.	1.7	40
63	Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study. <i>Nutrients</i> , 2020, 12, 1070.	1.7	27
64	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. <i>Clinical Neurophysiology</i> , 2020, 131, 1287-1310.	0.7	123
65	The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 637-643.	1.0	2
66	Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 348-355.	1.1	39
67	Disproportionate Impairment in Naming and Comprehension of Nouns with Relative Sparing of Verbs in a Patient who Survived Herpes Simplex Encephalitis. <i>International Journal of Speech & Language Pathology and Audiology</i> , 2020, 8, 29-37.	0.2	2
68	ORO-Dental Manifestations in West Syndrome. <i>Current Topics in Medicinal Chemistry</i> , 2020, 19, 2824-2828.	1.0	7
69	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	0.8	4
70	Delusions in dementias. , 2020, , 647-664.		0
71	Klotho at the Edge of Alzheimer's Disease and Senile Depression. <i>Molecular Neurobiology</i> , 2019, 56, 1908-1920.	1.9	26
72	Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. <i>Lancet</i> , 2019, 394, 639-651.	6.3	325

#	ARTICLE	IF	CITATIONS
73	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. <i>Alzheimer's and Dementia</i> , 2019, 15, 1019-1028.	0.4	47
74	Time to test antibacterial therapy in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2905-2929.	3.7	89
75	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 751-765.	1.5	0
76	Do anti-amyloid- β^2 drugs affect neuropsychiatric status in Alzheimer's disease patients?. <i>Ageing Research Reviews</i> , 2019, 55, 100948.	5.0	24
77	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 55.	2.4	32
78	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 599-602.	1.4	32
79	The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear. <i>Frontiers in Neuroscience</i> , 2019, 13, 619.	1.4	70
80	Rising rural body-mass index is the main driver of the global obesity epidemic in adults. <i>Nature</i> , 2019, 569, 260-264.	13.7	469
81	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1091-1107.	0.9	15
82	Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia. <i>Cortex</i> , 2019, 117, 257-265.	1.1	9
83	Disease-modifying therapies for tauopathies: agents in the pipeline. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 397-408.	1.4	15
84	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 4.	3.6	5
85	The Role of Biomarkers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 135-162.	0.8	29
86	Power Doppler Ultrasound Findings before and after Focused Extracorporeal Shock Wave Therapy for Achilles Tendinopathy: A Pilot Study on Pain Reduction and Neovascularization Effect. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1316-1323.	0.7	20
87	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β^2 , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
88	Multiple personality and hallucinations in a patient with normal dat-scan spect fulfilling diagnostic criteria for probable dementia with lewy bodies. <i>Journal of the Neurological Sciences</i> , 2019, 405, 120.	0.3	0
89	A critical appraisal of amyloid- β^2 -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
90	Are antibodies directed against amyloid- β^2 (A β^2) oligomers the last call for the A β^2 hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	1.0	50

#	ARTICLE	IF	CITATIONS
91	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231881100.	1.1	68
92	Response to Letter to the Editor: "Plasma β -amyloid $_{1-42}$ reference values", <i>Journal of the Neurological Sciences</i> , 2019, 396, 123-124.	0.3	0
93	Understanding frailty to predict and prevent dementia. <i>Lancet Neurology</i> , The, 2019, 18, 133-134.	4.9	19
94	Amyloid β immunotherapy for alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	2.8	126
95	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. <i>Drugs</i> , 2019, 79, 143-160.	4.9	38
96	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4333-4344.	1.9	19
97	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 699-711.	1.2	17
98	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 993-1012.	1.2	214
99	Comprehensive Geriatric Assessment in Long-Term Care and Nursing Homes. <i>Practical Issues in Geriatrics</i> , 2018, , 47-56.	0.3	0
100	Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	0.9	43
101	Genetics of tailored medicine: Focus on CNS drugs. <i>Microchemical Journal</i> , 2018, 136, 164-169.	2.3	1
102	An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities. <i>Rejuvenation Research</i> , 2018, 21, 3-14.	0.9	25
103	Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 162-168.	1.2	18
104	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
105	Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months?. <i>European Journal of Neurology</i> , 2018, 25, 203-204.	1.7	3
106	Sensory Changes and the Hearing Loss "Cognition Link. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 127.	1.2	16
107	CYP2D6 genotypes in revolving door patients with bipolar disorders. <i>Medicine (United States)</i> , 2018, 97, e11998.	0.4	26
108	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 847-857.	1.4	66

#	ARTICLE	IF	CITATIONS
109	Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 95, 480-498.	2.9	27
110	Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: a systematic review and meta-analysis of individual participant data. <i>Clinical Epidemiology</i> , 2018, Volume 10, 363-379.	1.5	49
111	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 989-1000.	1.2	42
112	Plasma β -amyloid 1 α -42 reference values in cognitively normal subjects. <i>Journal of the Neurological Sciences</i> , 2018, 391, 120-126.	0.3	19
113	Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S229-S254.	1.2	38
114	Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. , 2018, , 139-155.		3
115	Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder. <i>Molecular Neurobiology</i> , 2017, 54, 1340-1351.	1.9	28
116	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. <i>Alzheimer's and Dementia</i> , 2017, 13, 858-869.	0.4	24
117	Emerging biomarkers and screening for cognitive frailty. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	1.4	39
118	Long-term safety of repeated high doses of onabotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. <i>Journal of the Neurological Sciences</i> , 2017, 378, 182-186.	0.3	18
119	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 121-130.	1.2	41
120	Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 89.e1-89.e8.	1.2	126
121	Anti-tau vaccine in Alzheimer's disease: a tentative step. <i>Lancet Neurology</i> , The, 2017, 16, 99-100.	4.9	10
122	Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 192.e1-192.e11.	1.2	277
123	Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 815-849.	1.2	249
124	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. <i>Lancet</i> , The, 2017, 390, 2627-2642.	6.3	5,010
125	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	1.0	8
126	Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 927-935.	1.2	60

#	ARTICLE	IF	CITATIONS
127	Cognitive frailty: a potential target for secondary prevention of dementia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1023-1027.	1.5	40
128	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	1.3	36
129	Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity. Drugs, 2017, 77, 1413-1422.	4.9	7
130	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
131	Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. American Journal of Geriatric Psychiatry, 2017, 25, 1236-1248.	0.6	90
132	Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2536-2540.	0.7	17
133	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet, The, 2017, 389, 37-55.	6.3	1,667
134	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 259-277.	1.5	13
135	Evaluation of endothelial function and cardiovascular risk in non-obese patients with slight degree of obstructive sleep apnea syndrome. Monaldi Archives for Chest Disease, 2017, 87, 822.	0.3	4
136	Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review. Current Drug Targets, 2017, 18, 1487-1498.	1.0	38
137	Sensory impairments and cognitive disorders in older age. Geriatric Care, 2017, 3, .	0.2	0
138	Comprehensive geriatric assessment: evidence. , 2017, , 117-126.		6
139	Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-15.	0.9	138
140	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-14.	0.6	13
141	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. Journal of the American Geriatrics Society, 2016, 64, 1416-1424.	1.3	35
142	Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics, 2016, 16, 1357-1369.	1.4	10
143	Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology, 2016, 23, 1117-1125.	1.7	19
144	Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach. Journal of Alzheimer's Disease, 2016, 51, 427-437.	1.2	26

#	ARTICLE	IF	CITATIONS
145	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. <i>International Psychogeriatrics</i> , 2016, 28, 1111-1124.	0.6	19
146	Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 973-979.	1.2	23
147	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. <i>Lancet, The</i> , 2016, 387, 1513-1530.	6.3	2,842
148	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. <i>Lancet, The</i> , 2016, 387, 1377-1396.	6.3	3,941
149	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1624-1630.	0.7	52
150	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
151	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. <i>Journal of Orthopaedic and Sports Physical Therapy</i> , 2016, 46, 714-725.	1.7	21
152	Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. <i>Immunotherapy</i> , 2016, 8, 1119-1134.	1.0	61
153	Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 124-135.	3.0	4
154	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	2.8	56
155	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 981-989.	1.2	22
156	Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 505-515.	1.2	27
157	The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 431-442.	0.4	6
158	High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 843-846.	1.5	10
159	The Role of Hearing Impairment in Cognitive Decline: Need for the Special Sense Assessment in Evaluating Cognition In Older Age. <i>Neuroepidemiology</i> , 2016, 46, 290-291.	1.1	8
160	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1069-1077.	1.2	52
161	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthionium. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 259-277.	1.4	35
162	Tau aggregation inhibitors: the future of Alzheimer's disease pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 457-461.	0.9	17

#	ARTICLE	IF	CITATIONS
163	Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 678-679.	0.9	15
164	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 793-813.	1.2	108
165	Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 889-899.	1.2	51
166	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
167	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. <i>Toxins</i> , 2015, 7, 3045-3056.	1.5	33
168	Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 113.	1.7	67
169	Postural and Balance Disorders in Patients with Parkinson's Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	11
170	Measuring pharmacogenetics in special groups: geriatrics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1073-1088.	1.5	23
171	Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment. <i>Pain Medicine</i> , 2015, 16, 2012-2023.	0.9	12
172	Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. <i>BMJ Open</i> , 2015, 5, e007069.	0.8	25
173	A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 965-975.	1.3	34
174	Epidemiology of age related hearing loss: A review. <i>Hearing, Balance and Communication</i> , 2015, 13, 77-81.	0.1	20
175	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. <i>Journal of the Neurological Sciences</i> , 2015, 350, 1-6.	0.3	42
176	Age-related hearing impairment is a risk factor and frailty marker for dementia and AD. <i>Nature Reviews Neurology</i> , 2015, 11, 166-175.	4.9	192
177	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 624-637.	5.5	139
178	Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2015, 262, 593-603.	1.8	56
179	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. <i>Rejuvenation Research</i> , 2015, 18, 389-412.	0.9	112
180	Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. <i>Journal of Psychopharmacology</i> , 2015, 29, 623-633.	2.0	18

#	ARTICLE	IF	CITATIONS
181	Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2581-2588.	0.9	43
182	Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 313-328.	1.5	154
183	Caregiver burden characterization in patients with Alzheimer's disease or vascular dementia. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 891-899.	1.3	61
184	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
185	Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. <i>Clinical Rehabilitation</i> , 2015, 29, 50-58.	1.0	32
186	Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study. <i>PLoS ONE</i> , 2015, 10, e0130946.	1.1	41
187	Nutrition, frailty, and Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 221.	1.7	16
188	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 973-986.	1.4	42
189	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
190	Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. <i>Journal of the Neurological Sciences</i> , 2014, 347, 39-43.	0.3	47
191	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. <i>Current Opinion in Psychiatry</i> , 2014, 27, 128-137.	3.1	86
192	Possible role of alpha-lipoic acid in the treatment of peripheral nerve injuries. <i>Journal of Brachial Plexus and Peripheral Nerve Injury</i> , 2014, 05, e1-e2.	1.0	9
193	Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study. <i>Topics in Stroke Rehabilitation</i> , 2014, 21, S17-S24.	1.0	46
194	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1465-1476.	1.4	63
195	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. <i>Current Nutrition Reports</i> , 2014, 3, 110-129.	2.1	9
196	An intrinsically safe facility for forefront research and training on nuclear technologies – A zero-power experiment. <i>European Physical Journal Plus</i> , 2014, 129, 1.	1.2	0
197	Prevalence of diabetes and depressive symptomatology and their effect on mortality risk in elderly Italians: The Italian Longitudinal Study on Aging. <i>Diabetes and Metabolism</i> , 2014, 40, 373-378.	1.4	12
198	Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 634-647.	5.5	591

#	ARTICLE	IF	CITATIONS
199	Plant-Based Nutraceutical Interventions against Cognitive Impairment and Dementia: Meta-Analytic Evidence of Efficacy of a Standardized Ginkgo biloba Extract. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 605-611.	1.2	28
200	Mediterranean Diet and Cognitive Decline. A Lesson from the Whole-Diet Approach: What Challenges Lie Ahead?. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 283-286.	1.2	48
201	Perspective: The Challenge of Clinical Decision-Making for Drug Treatment in Older People. The Role of Multidimensional Assessment and Prognosis. <i>Frontiers in Medicine</i> , 2014, 1, 61.	1.2	13
202	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155
203	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Age</i> , 2013, 35, 441-453.	3.0	35
204	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. <i>Journal of Neural Transmission</i> , 2013, 120, 469-476.	1.4	32
205	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
206	SBOTE Study: Extracorporeal Shock Wave Therapy Versus Electrical Stimulation After Botulinum Toxin Type A Injection for Post-Stroke Spasticity—A Prospective Randomized Trial. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 283-291.	0.7	61
207	Vascular factors predict polyneuropathy in a non-diabetic elderly population. <i>Neurological Sciences</i> , 2013, 34, 955-962.	0.9	13
208	Neutron flux characterization of the SM1 sub-critical multiplying complex of the Pavia University. <i>Progress in Nuclear Energy</i> , 2013, 67, 98-103.	1.3	11
209	Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 113-122.	0.4	140
210	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 67-77.	0.6	8
211	Incidence of dementia: evidence for an effect modification by gender. The ILSA Study. <i>International Psychogeriatrics</i> , 2013, 25, 1867-1876.	0.6	24
212	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. <i>Molecular Psychiatry</i> , 2013, 18, 461-470.	4.1	103
213	Neuropsychiatric Symptoms and Functional Status in Alzheimer's Disease and Vascular Dementia Patients. <i>Current Alzheimer Research</i> , 2012, 9, 759-771.	0.7	75
214	Addition of the Multidimensional Prognostic Index to the Estimated Glomerular Filtration Rate Improves Prediction of Long-Term All-Cause Mortality in Older Patients with Chronic Kidney Disease. <i>Rejuvenation Research</i> , 2012, 15, 82-88.	0.9	43
215	Immunotherapy for Alzheimer's disease: from anti- β -amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	1.0	121
216	A Multidimensional Prognostic Index in Common Conditions Leading to Death in Older Patients. <i>Archives of Internal Medicine</i> , 2012, 172, 594; discussion 594-5.	4.3	18

#	ARTICLE	IF	CITATIONS
217	Changes in severity of depressive symptoms and mortality: the Italian Longitudinal Study on Aging. <i>Psychological Medicine</i> , 2012, 42, 2619-2629.	2.7	16
218	Treatment of Upper Limb Spasticity after Stroke: One-Year Safety and Efficacy of Botulinum Toxin Type A NT201. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 57-62.	1.0	6
219	Treatment of Late-Life Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors Improves the Multidimensional Prognostic Index. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 726-729.	0.7	20
220	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. <i>Future Neurology</i> , 2012, 7, 395-401.	0.9	1
221	Advances in the identification of β -secretase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 19-37.	2.5	45
222	Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis. <i>Age</i> , 2012, 34, 949-968.	3.0	8
223	Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults. <i>Rejuvenation Research</i> , 2012, 15, 281-287.	0.9	26
224	TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 731-740.	1.2	20
225	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. <i>Ageing Research Reviews</i> , 2012, 11, 87-103.	5.0	57
226	Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 135-149.	1.3	79
227	Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S31-S75.	1.2	44
228	Comparing the Prognostic Accuracy for All-Cause Mortality of Frailty Instruments: A Multicentre 1-Year Follow-Up in Hospitalized Older Patients. <i>PLoS ONE</i> , 2012, 7, e29090.	1.1	161
229	Effectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case report. <i>Journal of Rehabilitation Medicine</i> , 2012, 44, 795-797.	0.8	15
230	Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1218-1238.	1.3	90
231	Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. <i>Age</i> , 2012, 34, 507-517.	3.0	51
232	A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. <i>Journal of Neurology</i> , 2012, 259, 670-678.	1.8	46
233	Metabolic syndrome as a risk factor for neurological disorders. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 741-762.	2.4	164
234	Usefulness of the multidimensional prognostic index (MPI) in the management of older patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2012, 25, 79-84.	0.9	16

#	ARTICLE	IF	CITATIONS
235	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	0
236	Genetic variation in MME in relation to neprilysin protein and enzyme activity, A β levels, and Alzheimer's disease risk. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2012, 3, 30-8.	0.4	13
237	Monoclonal antibodies against β -amyloid (A β) for the treatment of Alzheimer's disease: the A β target at a crossroads. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 679-686.	1.4	40
238	Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship. <i>Brain Research Reviews</i> , 2011, 67, 344-355.	9.1	34
239	Therapeutic intervention for Alzheimer's disease with β -secretase inhibitors: still a viable option?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 325-341.	1.9	86
240	The Genetics of the Human APOE Polymorphism. <i>Rejuvenation Research</i> , 2011, 14, 491-500.	0.9	81
241	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 677-708.	1.4	231
242	Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology. <i>Progress in Lipid Research</i> , 2011, 50, 313-330.	5.3	172
243	Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2011, 32, 1932-1941.	1.5	108
244	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. <i>Neurobiology of Aging</i> , 2011, 32, 756.e11-756.e15.	1.5	82
245	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	18
246	Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice. <i>Current Drug Metabolism</i> , 2011, 12, 621-634.	0.7	17
247	Mediterranean Diet in Predementia and Dementia Syndromes. <i>Current Alzheimer Research</i> , 2011, 8, 520-542.	0.7	73
248	The APOE Gene Locus in Frontotemporal Dementia and Primary Progressive Aphasia. <i>Archives of Neurology</i> , 2011, 68, 622-8.	4.9	25
249	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
250	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. <i>Molecular Psychiatry</i> , 2011, 16, 903-907.	4.1	529
251	Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy. <i>Child's Nervous System</i> , 2011, 27, 2187-2192.	0.6	26
252	Different models of frailty in predementia and dementia syndromes. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 711-719.	1.5	76

#	ARTICLE	IF	CITATIONS
253	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. <i>Age</i> , 2011, 33, 409-419.	3.0	6
254	The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1062-1070.	1.3	27
255	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. <i>Current Alzheimer Research</i> , 2011, 8, 492-509.	0.7	67
256	Anti- β -Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. <i>Current Alzheimer Research</i> , 2011, 8, 808-817.	0.7	51
257	Interacting with γ -Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. <i>Current Medicinal Chemistry</i> , 2011, 18, 5430-5447.	1.2	26
258	Aluminium in the Diet, Cognitive Decline and Dementia. , 2011, , 2829-2850.		0
259	Alcohol Consumption in Predementia and Dementia Syndromes. , 2011, , 3011-3044.		0
260	Dietary Fatty Acids, Cognitive Decline, and Dementia. , 2011, , 2851-2883.		0
261	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 691-724.	1.2	139
262	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 247-255.	1.2	54
263	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 17-30.	1.2	78
264	Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 715-740.	1.2	149
265	Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1179-1183.	1.2	6
266	Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. <i>Journal of Neurology</i> , 2010, 257, 139-141.	1.8	18
267	Apolipoprotein E-related all-cause mortality in hospitalized elderly patients. <i>Age</i> , 2010, 32, 411-420.	3.0	5
268	EFFECT OF DONEPEZIL ON THE CONTINUUM OF DEPRESSIVE SYMPTOMS, MILD COGNITIVE IMPAIRMENT, AND PROGRESSION TO DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 389-390.	1.3	6
269	PLASMA LEVELS OF ω 3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DECLINE: POSSIBLE ROLE OF DEPRESSIVE SYMPTOMS AND APOLIPOPROTEIN E GENOTYPING. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2249-2251.	1.3	4
270	PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 2429-2430.	1.3	20

#	ARTICLE	IF	CITATIONS
271	Alcohol consumption and metabolic syndrome in the elderly: results from the Italian longitudinal study on aging. <i>European Journal of Clinical Nutrition</i> , 2010, 64, 297-307.	1.3	46
272	Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 867-870.	1.2	12
273	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	119
274	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 424-431.	0.7	6
275	Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: A case report. <i>Journal of Rehabilitation Medicine</i> , 2010, 42, 891-894.	0.8	12
276	Dietary Patterns and Protection Against Alzheimer Disease and Cognitive Decline. <i>Archives of Neurology</i> , 2010, 67, 1285.	4.9	5
277	Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke. <i>Brain Injury</i> , 2010, 24, 1108-1112.	0.6	12
278	Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 433-440.	0.9	100
279	Bapineuzumab: anti- β -amyloid monoclonal antibodies for the treatment of Alzheimer's disease. <i>Immunotherapy</i> , 2010, 2, 767-782.	1.0	52
280	Towards Disease-Modifying Treatment of Alzheimer's Disease: Drugs Targeting β -Amyloid. <i>Current Alzheimer Research</i> , 2010, 7, 40-55.	0.7	109
281	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 98-116.	0.6	502
282	Polymorphisms in Glutathione S-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. <i>Rejuvenation Research</i> , 2010, 13, 645-652.	0.9	23
283	Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report. <i>Journal of Chiropractic Medicine</i> , 2010, 9, 132-137.	0.3	13
284	Interleukin β 174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 177-182.	2.5	27
285	Alcohol consumption and cardiovascular risk factors in older lifelong wine drinkers: The Italian Longitudinal Study on Aging. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 647-655.	1.1	52
286	Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. <i>Ageing Research Reviews</i> , 2010, 9, 184-199.	5.0	112
287	Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. <i>Ageing Research Reviews</i> , 2010, 9, 399-417.	5.0	292
288	Pharmacogenetics of cytochrome P450 (CYP) in the elderly. <i>Ageing Research Reviews</i> , 2010, 9, 457-474.	5.0	53

#	ARTICLE	IF	CITATIONS
289	REVIEW: Î³â€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	1.9	63
290	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	1.2	69
291	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PProject on Epidemiology of Alzheimerâ€™s disease (IPREA). Aging Clinical and Experimental Research, 2010, 22, 440-449.	1.4	22
292	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	1.2	42
293	LRP-1 variation is not associated with risk of Alzheimer's disease. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 104-13.	0.4	8
294	Cognitive behavioural group therapy in mild cognitive impairment: Intervention with a cognitive or behavioural/psychological focus?. Journal of Rehabilitation Medicine, 2009, 41, 293-294.	0.8	1
295	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. Scientific World Journal, The, 2009, 9, 373-389.	0.8	24
296	Dietary Fatty Acids and Predementia Syndromes. Scientific World Journal, The, 2009, 9, 792-810.	0.8	10
297	All-Cause Mortality and Competing Risks of Fatal and Nonfatal Vascular Events in the Italian Longitudinal Study on Aging: Impact of Lipoprotein(a). Rejuvenation Research, 2009, 12, 395-402.	0.9	4
298	Mediterranean Dietary Pattern, Mild Cognitive Impairment, and Progression to Dementia. Archives of Neurology, 2009, 66, 910.	4.9	5
299	The Multidimensional Prognostic Index (MPI), Based on a Comprehensive Geriatric Assessment Predicts Short- and Long-Term Mortality in Hospitalized Older Patients with Dementia. Journal of Alzheimer's Disease, 2009, 18, 191-199.	1.2	77
300	Moderate Alcohol Consumption, Apolipoprotein E, and Neuroprotection. Archives of Neurology, 2009, 66, 538.	4.9	17
301	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	9.4	2,155
302	Role of Biphosphonates and Lymphatic Drainage Type Leduc in the Complex Regional Pain Syndrome (Shoulderâ€™Hand Syndrome). Pain Medicine, 2009, 10, 179-185.	0.9	9
303	RESPONSE LETTER TO DR. MELO ET AL.. Journal of the American Geriatrics Society, 2009, 57, 180-181.	1.3	1
304	APOLIPOPROTEIN E, DEMENTIA, AND HUMAN LONGEVITY. Journal of the American Geriatrics Society, 2009, 57, 740-742.	1.3	7
305	POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENTâ€™NO DEMENTIA. Journal of the American Geriatrics Society, 2009, 57, 943-944.	1.3	3
306	Wholeâ€™Diet Approach: Working on a Criterion Validity for Ageâ€™Related Cognitive Decline and Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2009, 57, 1944-1946.	1.3	13

#	ARTICLE	IF	CITATIONS
307	Short-term Effects of High-Intensity Laser Therapy Versus Ultrasound Therapy in the Treatment of People With Subacromial Impingement Syndrome: A Randomized Clinical Trial. <i>Physical Therapy</i> , 2009, 89, 643-652.	1.1	154
308	Higher total cholesterol, cognitive decline, and dementia. <i>Neurobiology of Aging</i> , 2009, 30, 546-548.	1.5	18
309	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1518-1520.	1.5	11
310	Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. <i>Ageing Research Reviews</i> , 2009, 8, 214-236.	5.0	46
311	Disease-Modifying Approach to the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2009, 26, 537-555.	1.3	80
312	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β -amyloid and tau protein. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 386-406.	1.4	47
313	N-3 polyunsaturated fatty acids and statins in heart failure. <i>Lancet</i> , The, 2009, 373, 380.	6.3	0
314	Temporal Relationship between Depressive Symptoms and Cognitive Impairment: The Italian Longitudinal Study on Aging. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 899-911.	1.2	49
315	Acoustic analysis of swallowing sounds: A new technique for assessing dysphagia. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 639-645.	0.8	58
316	Possible Role of S-Adenosylmethionine, S-Adenosylhomocysteine, and Polyunsaturated Fatty Acids in Predementia Syndromes and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 467-470.	1.2	23
317	Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 7-31.	1.2	98
318	Botulinum Toxin Type A in the Treatment of Focal Hand Dystonia After Surgical Treatment for Thumb Duplication. <i>Orthopedics</i> , 2009, 32, 529.	0.5	2
319	Botulinum Toxin Type A in the Treatment of Painful Adductor Muscle Contracture After Total Hip Arthroplasty. <i>Orthopedics</i> , 2009, 32, .	0.5	8
320	Vascular risk factors, alcohol intake, and cognitive decline. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 376-381.	1.5	29
321	Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, 382-386.	1.5	46
322	Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 726-734.	1.3	62
323	BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SIALORRHEA IN PARKINSON'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 765-767.	1.3	21
324	BEYOND CORONARY ARTERY DISEASE: ROSUVASTATIN IN OLDER PATIENTS WITH ISCHEMIC SYSTOLIC HEART FAILURE. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1366-1367.	1.3	2

#	ARTICLE	IF	CITATIONS
325	MILD COGNITIVE IMPAIRMENT: DEMENTIA RISK FACTOR OR HIGH-RISK STATE FOR PROGRESSION TO DEMENTIA?. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1367-1369.	1.3	3
326	Lifestyle-related factors in predementia and dementia syndromes. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 133-158.	1.4	129
327	Depressive Symptoms, Vascular Risk Factors and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 336-346.	0.7	38
328	Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms. <i>Neuroscience Letters</i> , 2008, 432, 237-242.	1.0	18
329	Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. <i>Neuroscience Letters</i> , 2008, 438, 335-339.	1.0	10
330	S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in predementia syndromes and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 478-480.	1.5	4
331	Hypertension and Mild Cognitive Impairment Subtypes. <i>Archives of Neurology</i> , 2008, 65, 992.	4.9	6
332	Association Analysis of <i>GRIN2B</i> , Encoding N-Methyl-D-Aspartate Receptor 2B Subunit, and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 287-292.	0.7	20
333	Alcohol Use, Thiamine Deficiency, and Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2853.	3.8	12
334	The RELN Locus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 335-344.	1.2	56
335	Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: A case for switching therapy?. <i>Journal of Rehabilitation Medicine</i> , 2008, 40, 882-883.	0.8	4
336	EFFECT OF A CLINICAL STROKE ON THE RISK OF DEMENTIA IN A PROSPECTIVE COHORT. <i>Neurology</i> , 2007, 68, 1748-1749.	1.5	0
337	Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline. <i>Neurology</i> , 2007, 68, 964-965.	1.5	8
338	Ten-year risk of dementia in subjects with mild cognitive impairment. <i>Neurology</i> , 2007, 68, 1238-1239.	1.5	1
339	CIND AND MCI IN THE ITALIAN ELDERLY: FREQUENCY, VASCULAR RISK FACTORS, PROGRESSION TO DEMENTIA. <i>Neurology</i> , 2007, 69, 2186-2187.	1.5	53
340	Progression to Dementia in Probable and Possible Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1209.	4.9	2
341	Alcohol consumption, mild cognitive impairment, and progression to dementia. <i>Neurology</i> , 2007, 68, 1790-1799.	1.5	133
342	Whole-Diet Approach, Mediterranean Diet, and Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 606.	4.9	6

#	ARTICLE	IF	CITATIONS
343	Apolipoprotein E Genotypes in Hospitalized Elderly Patients with Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 327-333.	0.7	26
344	Incident Occurrence of Depressive Symptoms among Patients with Mild Cognitive Impairment â€” The Italian Longitudinal Study on Aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 55-64.	0.7	66
345	Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. <i>Neurobiology of Aging</i> , 2007, 28, 1631-1632.	1.5	23
346	Lipoproteins, Vascular-Related Genetic Factors, and Human Longevity. <i>Rejuvenation Research</i> , 2007, 10, 441-458.	0.9	25
347	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. <i>Atherosclerosis</i> , 2007, 193, 455-457.	0.4	6
348	Possible Role of Unsaturated Fatty Acids in a 14-Day Healthy Longevity Lifestyle Program. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 266.	0.6	4
349	TOTAL CHOLESTEROL LEVELS AND THE RISK OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 133-135.	1.3	15
350	DIETARY POLYUNSATURATED FATTY ACID SUPPLEMENTATION, PREDEMENTIA SYNDROMES, AND ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 469-470.	1.3	9
351	CHANGE OF DIAGNOSES IN PROBABLE AND POSSIBLE MILD COGNITIVE IMPAIRMENT: THE ITALIAN LONGITUDINAL STUDY ON AGING. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1480-1482.	1.3	2
352	LIFESTYLE-RELATED FACTORS, ALCOHOL CONSUMPTION, AND MILD COGNITIVE IMPAIRMENT. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1679-1681.	1.3	11
353	The Missing ApoE Allele. <i>Annals of Human Genetics</i> , 2007, 71, 496-500.	0.3	21
354	Interleukin 6 Variable Number of Tandem Repeats (VNTR) Gene Polymorphism in Centenarians. <i>Annals of Human Genetics</i> , 2007, 71, 843-848.	0.3	13
355	Mediterranean diet, mild cognitive impairment, and Alzheimer's disease. <i>Experimental Gerontology</i> , 2007, 42, 6-7.	1.2	22
356	Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. <i>Aging Clinical and Experimental Research</i> , 2006, 18, 144-148.	1.4	17
357	Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2006, 188, 455-461.	0.4	42
358	Circulating biomarkers of cognitive decline and dementia. <i>Clinica Chimica Acta</i> , 2006, 364, 91-112.	0.5	124
359	Nutritional factors, cognitive decline, and dementia. <i>Brain Research Bulletin</i> , 2006, 69, 1-19.	1.4	83
360	Cognitive frailty: Predementia syndrome and vascular risk factors. <i>Neurobiology of Aging</i> , 2006, 27, 933-940.	1.5	140

#	ARTICLE	IF	CITATIONS
361	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1537-1553.	1.5	22
362	Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Neurobiology of Aging</i> , 2006, 27, 1694-1704.	1.5	222
363	Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 303-330.	1.2	44
364	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. <i>Vascular Disease Prevention</i> , 2006, 3, 235-245.	0.2	0
365	PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1474-1475.	1.3	3
366	DIET, CHOLESTEROL METABOLISM, AND ALZHEIMER'S DISEASE: APOLIPOPROTEIN E AS A POSSIBLE LINK?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1963-1965.	1.3	9
367	WHOLE-DIET APPROACH AND RISK OF CHRONIC DISEASE: LIMITS AND ADVANTAGES. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1800-1802.	1.3	19
368	APOLIPOPROTEIN E GENOTYPES IN MILD COGNITIVE IMPAIRMENT SUBTYPES. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1965-1966.	1.3	11
369	Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2006, 41, 619-627.	1.2	75
370	Serum total cholesterol as a biomarker for Alzheimer's disease: Mid-life or late-life determinations?. <i>Experimental Gerontology</i> , 2006, 41, 805-806.	1.2	14
371	Cardiovascular Factors and Cognitive Impairment: A Role for Unsaturated Fatty Acids and Mediterranean Diet?. <i>American Journal of Cardiology</i> , 2006, 98, 1120-1121.	0.7	7
372	Lipid metabolism in cognitive decline and dementia. <i>Brain Research Reviews</i> , 2006, 51, 275-292.	9.1	165
373	Candidate genes for late-onset Alzheimer's disease: Focus on chromosome 12. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 36-47.	2.2	16
374	Adherence to a Mediterranean dietary pattern and risk of Alzheimer's disease. <i>Annals of Neurology</i> , 2006, 60, 620-620.	2.8	13
375	Low incidence for predementia and dementia syndromes in a brain imaging study. <i>Annals of Neurology</i> , 2006, 60, 619-619.	2.8	0
376	Sex Differences in the Association of Apolipoprotein E and Angiotensin-Converting Enzyme Gene Polymorphisms With Healthy Aging and Longevity: A Population-Based Study From Southern Italy. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 918-923.	1.7	70
377	Stroke and Memory Decline: A Question of Degenerative or Vascular Origin. <i>Archives of Neurology</i> , 2006, 63, 1347.	4.9	1
378	Dietary fatty acids intake: possible role in cognitive decline and dementia. <i>Experimental Gerontology</i> , 2005, 40, 257-270.	1.2	113

#	ARTICLE	IF	CITATIONS
379	Unsaturated fatty acids intake and all-causes mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. <i>Experimental Gerontology</i> , 2005, 40, 335-343.	1.2	33
380	Polymorphisms in the Oxidized Low-Density Lipoprotein Receptor-1 Gene and Risk of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 280-284.	1.7	20
381	Molecular Determinants of Human Longevity. <i>Advances in Clinical Chemistry</i> , 2005, 39, 185-210.	1.8	1
382	The Cathepsin D Gene Exon 2 (C224T) Polymorphism and Sporadic Alzheimer's Disease in European Populations. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 991-996.	1.7	14
383	Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 633-644.	0.6	171
384	Italian Project on Epidemiology of Alzheimer's disease (I.P.R.E.A.): study design and methodology of cross-sectional survey. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 29-34.	1.4	18
385	Current epidemiology of mild cognitive impairment and other predementia syndromes. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 633-44.	0.6	109
386	Vascular risk factors, incidence of MCI, and rates of progression to dementia. <i>Neurology</i> , 2004, 63, 1882-1891.	1.5	482
387	Mediterranean diet and cognitive decline. <i>Public Health Nutrition</i> , 2004, 7, 959-963.	1.1	173
388	Vascular genetic factors and human longevity. <i>Mechanisms of Ageing and Development</i> , 2004, 125, 169-178.	2.2	37
389	Interleukin 6 γ 174 G/C promoter gene polymorphism in centenarians: no evidence of association with human longevity or interaction with apolipoprotein E alleles. <i>Experimental Gerontology</i> , 2004, 39, 1109-1114.	1.2	35
390	Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. <i>Experimental Gerontology</i> , 2004, 39, 1567-1573.	1.2	63
391	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 69-89.	1.4	60
392	Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer's disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 126B, 69-73.	2.4	19
393	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: Different allele frequencies between the North and South of Europe. <i>Experimental Gerontology</i> , 2003, 38, 1015-1020.	1.2	66
394	Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1159-1161.	0.9	29
395	Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. <i>NeuroReport</i> , 2003, 14, 605-608.	0.6	52
396	Semantic Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 695-696.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Semantic Dementia: Neuropsychological and Behavioral Patterns in Relation to Hemispheric Asymmetries. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 695-696.	0.6	2
398	F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer's Disease. <i>European Neurology</i> , 2002, 47, 209-213.	0.6	10
399	Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 732-736.	0.9	81
400	Selective Attention Skills in Differentiating between Alzheimer's Disease and Normal Aging. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 99-109.	1.2	24
401	Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients ≥ 65 years of age (The Italian Longitudinal Study on Aging). <i>American Journal of Cardiology</i> , 2002, 89, 825-829.	0.7	37
402	Lipoprotein(a) in the elderly: beyond atherosclerosis. <i>Archives of Gerontology and Geriatrics</i> , 2002, 35, 337-343.	1.4	0
403	Serum apolipoprotein E levels in Alzheimer's disease and extreme longevity. <i>Archives of Gerontology and Geriatrics</i> , 2002, 35, 345-352.	1.4	5
404	Lack of association between ace polymorphism and Alzheimer's disease in southern Italy. <i>Archives of Gerontology and Geriatrics</i> , 2002, 35, 239-245.	1.4	8
405	Apolipoprotein and antitensin converting enzyme genes: regional differences and extreme longevity in Europe. <i>Archives of Gerontology and Geriatrics</i> , 2002, 35, 247-251.	1.4	4
406	Impact of decreased frequency of apolipoprotein E $\epsilon 4$ allele on Alzheimer's disease in Southern Italy. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 299-306.	1.4	1
407	Analysis of individual items of mini-mental state examination in discrimination between normal and demented subjects. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 357-362.	1.4	8
408	Apolipoprotein E in Southern Italy: protective effect of $\epsilon 2$ allele in early- and late-onset sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2000, 292, 79-82.	1.0	39
409	Decreased frequency of apolipoprotein E $\epsilon 4$ allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians. <i>Neuroscience Letters</i> , 1999, 277, 53-56.	1.0	75
410	Efficacy of Cytidine Diphosphate Choline in Patients Affected by Chronic Cerebrovascular Disease. <i>Clinical Drug Investigation</i> , 1996, 12, 26-38.	1.1	8
411	Non-Pharmacological Approaches in the Treatment of Dementia. , 0, , .		3